Abarceo Pharma
Abarceo Pharma is a spin-out of Lund University Diabetes Center founded in 2017 by Prof. Claes Wollheim, MD, and Associate Prof. Albert Salehi world-renowned scientists in diabetes research and beta-cell biology. Abarceo Pharma has identified a novel diabetes target VDAC1 located on beta cells and a novel mechanism of action enabling a therapeutic treatment to revert beta cells from dysfunctional to functional, preserving beta cell function and allowing patients to produce their insulin again, naturally. The company founders were the first to describe that voltage-dependent anion channel 1 (VDAC1) is dysfunctional and presents a novel target in Type 2 Diabetes (T2D). VDAC1 is a key mitochondrial protein regulating the energy production in cells and has been implicated in multiple diseases with underlying mitochondrial dysfunction including neurodegenerative and cardiovascular disease (CVD). These diseases are closely related to T2D and are often referred to as comorbidities.
Abarceo Pharma is developing a small molecule technology platform for the treatment of mitochondrial dysfunction, with an initial focus on T2D.
Anatomic Studios
- CEO: Anders Wallseth
- Chairman of the board: Mette Gross
Anatomic Studios’ mission is to bring empowerment and self-expression to users of assistive devices. We provide personlized high-quality prosthetic covers to amputees around the world.
Anatomic studios has developed a range of designs and built a digital platform for ordering, scanning, 3D-modelling and production that enables rapid global expansion. In 2025 the order entry grew 100% and the plan for 2026 is to double the revenue.
The customer base consists of a rapidly growing number of orthopedic clinics that are approached both through direct sales efforts and digital marketing. In parallel, demand from end users is increased through social media and Google Ads.
Amplio Pharma
- CEO: Marguerite Mensonides
- Chairman of the board: Rob Mayfield
Amplio Pharma is a rare opportunity to invest in a de-risked, patent-protected asset with the potential to redefine first-line rheumatoid arthritis treatment. NovoBioJect builds on methotrexate, the established global standard, and has already generated human biomarker data supporting superior efficacy. Rather than competing in crowded biologics markets, it aims to replace the current first-line therapy, creating access to a multi-billion-dollar market opportunity. With Phase IIa ahead, €10 million of Series A financing, and a defined acquisition pathway by major immunology players, Amplio offers investors a realistic near-term exit opportunity and the potential for outsized returns.
AlzeCure
- Interim CEO: Johan Sandin
- Chairman of the board: Thomas Pollare
AlzeCure® is a Swedish biotech company developing new, innovative drug therapies for severe diseases and conditions affecting the central nervous system, such as Alzheimer’s disease and pain – indications where available treatment options today are very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several drug candidates in parallel based on three research platforms: NeuroRestore®, Alzstatin® and Painless. AlzeCure has recently signed collaboration and outlicensing agreements with Eli Lilly on the Alzstatin platform, and with QuantumCell ApS on the NeuroRestore platform.
Aventera Antibodies
- CEO: Arman Izadi
- Chairman of the board: Göran Forsberg
Aventera develops a novel class of super-potent antibodies, with a first-in-class mAb against life-threatening group A strep disease, planned for clinical trials in 2028
Biovica
- CEO: Theis Kipling
- Chairman of the board: Jeff Borcherding
Biovica develops DiviTum® TKa, a blood-based biomarker test that tells oncologists within weeks, not months, whether a metastatic breast cancer treatment is working. Instead of waiting ~12 weeks for the first imaging scan, a simple blood draw gives an early signal of treatment response, enabling faster course-correction for patients and supporting smarter dosing and patient stratification for pharma partners. Our promise: replace a long, uncertain wait with an early, actionable answer, so fewer patients stay on treatments that aren’t working, and more decisions get made when they still matter most.
Biomedical Bonding
- CEO: Michael Malkoch
- Chairman of the board: Michael Malkoch
Every second, more than five people somewhere in the world break a bone. Most of us will break at least two in a lifetime. Fracture is not a niche indication. It is one of the few medical events almost every human being will experience.Yet the repair has barely changed in seventy years. A rigid metal plate is manufactured long before the injury exists, chosen from a catalogue of sizes and bent by hand to approximate a bone it was never made for. The compromise is sharpest where the need is greatest. In osteoporotic bone, screws lose their purchase, and a plate many times stiffer than the bone it supports shields that bone from load and concentrates stress at its ends, where the next fracture begins.
Biomedical Bonding AB is a Swedish MedTech company founded to remove that compromise. Bonevolent®, a patented light-cured composite platform spun out of KTH Royal Institute of Technology in Stockholm and grounded in more than a decade of research and peer-reviewed biomechanical evidence, allows the surgeon to build a load-bearing fixator directly on the bone and cure it on demand. The implant is shaped to the fracture rather than the fracture to the implant, and it cures to a stiffness close to bone itself.The human skeleton has 206 bones, and almost every one of them can break in a way that a fixator shaped in theatre fits better than anything made in advance. That is the scale BMB is building towards: veterinary market entry in 2027, the first human fracture fixed in 2028, followed by market launch in 2030.
BioInvent International
- CEO: Martin Welschof
- Chairman of the board: Leonard Kruimer
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with drug candidates in ongoing clinical programs in Phase 1/2 trials for the treatment of solid tumors and hematological cancer. Its validated, proprietary F.I.R.S.T™ technology platform identifies both targets and the antibodies that bind to them, generating many promising new immune-modulatory candidates to fuel the Company’s own clinical development pipeline and providing licensing and partnering opportunities. The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company’s fully integrated manufacturing unit. More information is available at www.bioinvent.com.
Cantargia
- CEO: Hilde H. Steineger
- Chairman of the board: Magnus Persson
Cantargia is a clinical-stage biotech company developing antibody therapies targeting IL1RAP, a key driver in cancer and inflammatory diseases. Our lead asset, nadunolimab, shows promising clinical activity in hard‑to‑treat cancers such as pancreatic cancer, addressing a major unmet medical need. In parallel, CAN10 creates significant value through a global partnership with Otsuka, including milestone payments and royalties. With a differentiated mechanism, advancing clinical programs, and strong partnering potential, Cantargia offers a compelling opportunity in high‑impact therapeutic areas.
Edvince
- CEO: Peter Selin
- Chairman of the board: Erik Kinnman
Edvince is a clinical-stage biotech developing novel treatments in the field of stroke. Edvince’s lead program, EDV2209 is a first-in-class candidate drug that has completed a clinical phase 1b/2a trial in patients with subarachnoid hemorrhage (SAH). EDV2209 has obtained Orphan Drug Designation in SAH by both FDA and EMA. The company is now planning to advance the program into Phase 2b and, in connection with this, list the company on NGM during Q4 2026.
Endoriz
- CEO: Hanne Evenbratt
- Chairman of the board: Sara Malcus
Endoriz is developing a next‑generation therapy for hypothyroidism, a common chronic disease where many patients remain symptomatic despite standard treatment. Millions—predominantly women—continue to suffer from fatigue, cognitive impairment, and reduced quality of life with no effective alternative. Endoriz addresses this unmet need with a patent‑pending, extended‑release therapy designed to restore natural hormone balance in a safe and controlled way. The program is structured to enter clinical development directly at Phase II, significantly reducing development time, cost, and risk. This positions Endoriz for rapid value inflection and high‑value partnering within a large, established endocrine market.
Elicera Therapeutics
- CEO: Johan Liwing
- Chairman of the board: Margareth Jorvid
Elicera Therapeutics develops cell and gene therapies armed with its patented iTANK platform, enabling a parallel immune attack against cancer. Lead candidate ELC-301 completed Phase I of the CARMA study in B-cell lymphoma: well tolerated, with objective responses in 10 of 11 patients, including patients relapsing after prior CAR T. Enrollment in Phase IIa is pending. In parallel, a first clinical study of the second candidate, ELC-401, in glioblastoma is being prepared. For CAR T and TCR-T developers, iTANK is a plug-in answer to antigen escape and immunosuppression in solid tumors, backed by first-in-human data and available under non-exclusive licenses.
Glycorex Transplantation
- CEO: Carl-Magnus Schultz
- Chairman of the board: Richard Lundin
Glycorex Transplantation AB (publ) (NGM: GTAB B) is a Swedish medtech pioneer with in-house R&D and manufacturing in Lund. Its proprietary immunoadsorption technology removes blood group antibodies. Flagship product Glycosorb® ABO facilitates blood group-incompatible organ and stem cell transplants—backed by 60+ publications and 8,000+ procedures across 30+ countries.Under new leadership focused on profitability, Glycorex is accelerating global expansion with new distribution in emerging markets. The platform is also scaling into universal blood components for transfusion centers, pre-hospital care, and military use.
Hamlet Biopharma
- CEO: Jakob Testad
- Chair of the board: Catharina Svanborg
Hamlet BioPharma takes molecular discoveries through drug development to the clinic. We have positive clinical data in three completed Phase II trials and a strong portfolio of new treatment concepts for cancer and infections, protected by about 180 patents.
Isofol Medical
- CEO: Petter Segelman Lindqvist
- Chairman of the board: Jan-Eric Österlund
Isofol is a clinical-stage biotechnology company dedicated to improving outcomes for patients with difficult-to-treat cancers. The company’s drug candidate, arfolitixorin, is a next-generation folate therapy designed to enhance the efficacy of established standard treatments for solid tumors. Arfolitixorin is initially and currently being evaluated in a Phase Ib/II clinical trial in metastatic colorectal cancer, the second leading cause of cancer-related death worldwide and an area of significant unmet medical need. Isofol is listed on Nasdaq Stockholm.
Lumito
- CEO: Sanna Wallenborg
- Chairman of the board: Kerstin Jakobsson
Lumito develops and markets innovative technology for advanced tissue analysis in research, drug development and digital pathology. The company’s patented SCIZYS® platform uses upconverting nanoparticles (UCNPs) to enable highly sensitive detection and quantitative analysis of proteins in tissue with minimal interfering background.
By providing more detailed, objective and reproducible biomarker information, SCIZYS® contributes to the development from predominantly visual and semi-quantitative biomarker assessment towards more sensitive, objective and quantitative analysis. This can support researchers in understanding disease mechanisms, evaluating biomarkers and advancing drug development. Lumito’s vision extends beyond today’s research applications, with the ambition to contribute to the development towards precision medicine, where better biological insights can ultimately support better diagnostics, treatment decisions and patient outcomes.
MagCath
- CEO: Rune Wessel Wetlesen
- Chair of the board: Camilla Harder Hartvig
Over 42 million women in the EU and US live with stress urinary incontinence, yet have no satisfactory option beyond pads or surgery. Obtinu is the first over-the-counter urethral insert with a magnetic open/close mechanism: discreet, non-surgical, on demand. Five clinical trials show 80%+ of users fully continent. We hold patents in the US, EU and China, CE mark since June 2026, and manufacturing in Denmark. We’re raising USD 2M at a USD 10M pre-money to launch in the Nordics in 2027, secure Class IIa and FDA submission, and reach positive cash flow in 2028. Join us in restoring control.
Orexo
- CEO: Nikolaj Sorensen
- Chairman of the board: Friedrich von Bohlen
Orexo is a Swedish pharmaceutical company. At the core of our innovation is AmorphOX®, an amorphous powder based proprietary drug delivery technology that improves bioavailability and stability for both large and small molecules, enabling new approaches to administration, manufacturing, and distribution. With over 30 years of experience and multiple drugs approved globally, Orexo is advancing a diversified pipeline of programs in clinical and preclinical development. The company collaborates with partners in research, development, and commercialization. Headquartered in Uppsala, Sweden, Orexo is listed on Nasdaq Stockholm’s main market and trades as ADRs on the OTCQX market in the United States.
Oxcia
- CEO: Ulrika Warpman Berglund
- Chairman of the board: Eva Sjökvist Saers
Oxcia AB is a clinical-stage biotech company pioneering therapies that target key drivers of many diseases, using its proprietary O2-DDR platform (Oxidative stress, Oxidative DNA damage, and DNA Damage Response (DDR)). The platform has so far generated two first-in-class drug candidates: OXC-101, currently in clinical development for acute myeloid leukemia with both FDA and EMA Orphan Drug Designations, and OXC-201, a novel treatment for idiopathic pulmonary fibrosis supported by European Innovation Council funding. By addressing major unmet medical needs through a differentiated scientific approach, Oxcia aims to deliver transformative therapies to make life less short, creating significant value for patients and investors.
Paindrainer
- CEO: Erik Frick
- Chairman of the board: Carl Borrebaeck
Paindrainer is a leading digital company with a proven business model and clinical evidence. It’s latest product is the first voice controlled digital tool powered by a proprietary agentic AL.
PharmNovo
- CEO: Per von Mentzer
- Chairman of the board: Johan Lund
PharmNovo is pioneering a pain-free future. Our lead candidate, PN6047, is a first-in-class, Phase II-ready delta opioid receptor agonist (DORA) targeting neuronal hypersensitivity disorders, with neuropathic pain and chronic cough as key indications. With its differentiated mechanism of action and compelling human safety and tolerability profile demonstrated in Phase I, PN6047 has the potential to offer a safer, non-addictive treatment approach, addressing significant unmet medical needs across multiple indications. With an estimated global peak sales potential exceeding €2 billion by 2041, PN6047 represents a potential blockbuster opportunity and a highly attractive future acquisition target. Awarded €17.5 million in blended financing support through the EIC Accelerator, PharmNovo is advancing towards Phase II clinical development, with an estimated exit potential exceeding €1 billion by 2028.
Reccan
- CEO: Anna Brodén
- Chairman of the board: Roland Andersson
Reccan is developing a blood-based test for the early detection of pancreatic cancer, a disease where early diagnosis is critical to survival. The product has reached full-scale manufacturing and is in clinical validation ahead of CE marking and commercialisation. The EU-funded SHIELD project strengthens the company’s position in Europe. In parallel, Reccan is developing a new, earlier-stage project focused on people over 50 with new-onset diabetes – a considerably larger at-risk population in which early identification of pancreatic cancer could create significant clinical and commercial opportunities. Reccan is seeking SEK 20–25 million to complete clinical validation and regulatory work and to prepare for market launch.
redhot Diagnostics
- CEO: Nina E Beer
- Chairman of the board: Johan Ryden
redhot Diagnostics commercializes standardized kits for LC-MS/MS, the gold-standard method in clinical chemistry. Most laboratories still run these tests on in-house protocols, so results vary from one laboratory to the next, and IVDR is steadily closing that route. redhot replaces the protocols with validated, CE-marked kits.The lead product measures PEth, a substance formed only in the presence of alcohol, giving it 100 percent biochemical specificity and a detection window of several weeks. It is used in addiction medicine, liver and transplant clinics, and clinical trials. The kit is on the market today, generating recurring revenue at gross margins above 90 percent with almost no commercial effort behind it.Kits for drug monitoring and vitamin B12 deficiency are in development, alongside rhelise™, a patented home-sampling kit that keeps a blood sample stable for more than two weeks at room temperature. A further application filed in 2026 covers improved calibrators and controls.redhot diagnostics is raising capital to expand European and US distribution and build a multi-marker LC-MS/MS platform.
Saniona
- CEO: Thomas Feldthus
- Chairman of the board: John Haurum
Saniona (Nasdaq Stockholm: SANION) is a clinical-stage biopharmaceutical company developing ion channel medicines for neurological and psychiatric disorders. Its two wholly owned programs are preparing for Phase 1: SAN2668, a GABA-A α2/α3 PAM for severe paediatric epilepsies (DEE), and SAN2465, a GABA-A α5 NAM designed as a rapid-acting oral antidepressant for Major Depressive Disorder (MDD). Built on decades of ion channel research, Saniona’s platform has generated over SEK 1.2 billion in partnership income since 2012, including recent deals with Jazz and Acadia worth USD 70.5 million upfront and up to USD 1.6 billion in milestones. Saniona is funded to take both programs through Phase 1.
SampleFacts
- CEO: Maryam Poorafshar
- Chairman of the board: Gunilla Lundmark
SampleFacts brings together more than 100 years of combined experience providing a deep understanding of sample collection, workflows and the challenges faced by healthcare and research.Our patented solution enables instant separation of blood cells and plasma from a single drop of blood, at the point of collection, without centrifugation. With these characteristics the product provides a reliable and simple method for collecting and storing blood samples, addressing the growing demand for remote and patient centric sampling and biobanking.SampleFacts’ solution revolutionizes the way we take blood samples, where our technology transforms sample collection and storage empowering health care, research and military with accuracy, efficiency and limitless applications.
SenzaGen
- CEO: Peter Nählstedt
- Chairman of the board: Carl Borrebaeck
Countless chemicals are part of our daily lives, making accurate safety testing essential. At SenzaGen, we provide non-animal testing methods that are more human-relevant and deliver higher predictive accuracy than traditional animal experiments. This includes our proprietary GARD® platform, powered by genomics and machine learning for advanced skin allergy assessments. With operations in Sweden, UK and Italy, we are driving the global shift toward safer, more ethical testing. Demand is growing rapidly, supported by strong sales growth, solid margins, and an expanding portfolio that strengthens our position in key industries. Learn more at www.senzagen.com.
Speed Care Mineral
- CEO: Siegfried Kruse
- Chairman of the board: Matthias Kurtz
Speed Care Mineral is unique developer and manufacturer of SpeedM, an emergency hemostatic dressing. Developed accoring advices from german bundeswehr, the technology stands for new requirements in modern warfare. Sourcing 100% NATO countries and resilient manufacturing in Germany stands for reliable growth. We are looking for €5M to for scale-up globally and expansion into Dual-Use indication in Gynecology and Cardiology.
Sprint Bioscience
- CEO: Johan Emilsson
- Chairman of the board: Björn Sjöstrand
Sprint Bioscience develops small molecule, first in class drug programs with a focus on oncology. Using a fragment based drug discovery approach, the company develops drug programs in a time and resource efficient manner.The programs are partnered through licensing agreements, asset acquisitions, or research collaborations with global pharmaceutical companies during the preclinical phase, and the company has successfully entered into several such agreements.Sprint Bioscience is headquartered in Stockholm, Sweden, with laboratories located in Huddinge. The company’s shares are listed on Nasdaq First North Premier Growth Market (ticker: SPRINT).
Strike Pharma
- CEO: Per Norlén
- Chairman of the board: Magnus Persson
Pipeline of first in class in vivo CAR-M therapies based on a proprietary technology for targeted LNP delivery that improves potency and stability of products while reducing manufacturing costs.
Sox Therapeutics
- CEO: Fredrik Swartling
- Chairman of the board: Christina Herder
Xbrane Biopharma
- CEO: Martin Åmark
- Chairman of the board: Anders Tullgren
Zelluna
- CEO: Namir Hassan
- Chairman of the board: Anders Tuv
